Maximal changes in paraprotein after CC-5013 treatment.
| . | . | Decrease . | Increase . | |||
|---|---|---|---|---|---|---|
| Dose (mg/d) . | Pts. (n . | < 25% . | ≥ 25%- < 50% . | ≥ 50%- <75% . | ≥ 75%- <99% . | 25% . |
| Reprinted with permission from Richardson P, Schlossman R, Hideshima T, et al. A phase I trial of oral CC 5013, an Immunomodulatory thalidomide derivative, in patients with relapsed and refractory multiple myeloma. Blood 2002; in press. | ||||||
| 5 | 3 | 0 | 2 | 1 | 0 | 0 |
| 10 | 5 | 0 | 0 | 1 | 0 | 4 |
| 25 | 3 | 1 | 2 | 0 | 0 | 0 |
| 50 | 13 | 1 | 6 | 2 | 3 | 1 |
| Total | 24 | 2 (8%) | 10 (42%) | 4 (17%) | 3 (13%) | 5 (21%) |
| . | . | Decrease . | Increase . | |||
|---|---|---|---|---|---|---|
| Dose (mg/d) . | Pts. (n . | < 25% . | ≥ 25%- < 50% . | ≥ 50%- <75% . | ≥ 75%- <99% . | 25% . |
| Reprinted with permission from Richardson P, Schlossman R, Hideshima T, et al. A phase I trial of oral CC 5013, an Immunomodulatory thalidomide derivative, in patients with relapsed and refractory multiple myeloma. Blood 2002; in press. | ||||||
| 5 | 3 | 0 | 2 | 1 | 0 | 0 |
| 10 | 5 | 0 | 0 | 1 | 0 | 4 |
| 25 | 3 | 1 | 2 | 0 | 0 | 0 |
| 50 | 13 | 1 | 6 | 2 | 3 | 1 |
| Total | 24 | 2 (8%) | 10 (42%) | 4 (17%) | 3 (13%) | 5 (21%) |